
|
 |
According to the:

Recommendations for Avian Influenza include:
Use of a fit-tested respirator, at least as protective
as a National Institute of Occupational Safety and
Health (NIOSH)-approved N-95 filtering facepiece (i.e.,
disposable) respirator, when entering the room.
|
OUR
RECOMMENDATIONS...
|
PREVENTATIVE
PRODUCTS: Masks, Barriers, and filters for Airborne
Pathogen Protection
|
|

ADULT SIZE NanoMasks:
|
|
Click
on the button above
to Buy ADULT BLUE Now Online...
Was $19.95
SALE $7.95 each
|
|
Click
on the button above
to Buy
ADULT
YELLOW Now Online...
Was
$19.95
SALE $7.95 each
|
|
Click
on the button above
to Buy
ADULT
MAGENTA Now Online...
Was
$19.95
SALE $7.95 each
|
|
Click
on the button above
to Buy
ADULT
GREEN Now Online...
Was
$19.95
SALE $7.95 each
|
|
Click
on the button above
to Buy
ADULT
RED Now Online...
Was
$19.95
SALE $7.95 each
|
CHILD
SIZE NanoMasks:
|
|
|
Click
on the button above
to Buy CHILD BLUE Now Online...
Was $19.95
SALE $7.95 each
|
|
Click
on the button above
to Buy CHILD YELLOW Now Online...
Was
$19.95
SALE $7.95 each
|
|
Click
on the button above
to Buy CHILD PURPLE Now Online...
Was
$19.95
SALE $7.95 each
|
|
Click
on the button above
to Buy CHILD GREEN Now Online...
Was
$19.95
SALE $7.95 each
|
|
Click
on the button above
to Buy CHILD RED Now Online...
Was
$19.95
SALE $7.95 each
SEE
SPECIAL "PACK" SAVINGS BELOW

See Nano
Mask Filter Replacements below and to the
right...
|
|
|
SKUS: WP-NM1-102 (B,R,Y,M,G) / WP-NM5-FP1
CHILD SIZE SKUS:
WP-NM2-100 (B,R,Y,P,G) / WP-NM5-FP2A higher level of protection (Click
here for NanoMask FAQs)
1. What is filtration efficiency?
Filtration efficiency is the measurement of a filters capacity to remove particulates, such as virus and bacterium, from air as it
flows through the filter. Filtration efficiency is stated as a percentage of efficiency and is affected by such factors as size of the
particulates to be filtered, volume of air and duration of use. An N-95 rated mask, for example, is 95% efficient at removing particles
with a median diameter of approximately 0.3 microns at a volume of 85 liters per minute. Duration of use is a critical factor because
virus and bacterium can infest the filter for extended periods of time. Bacteria can reproduce on their own while virus can survive
for days before infecting a living host. Virus and bacterium can also move through filters over time resulting in an erosion of
filtration efficiency and increase in the associated risk factors.
2. What is the filtration efficiency of the NanoMask?
The filtration efficiency of the filter material used in the NanoMask is 99%. We enhance this intrinsic filtration efficiency with a
coating of nano-particles. The nano-particles counteract the ability of pathogens to live and/or reproduce on the filter by eradicating
virus and bacterium that come into contact with the filter surface.
3. How do the nano-particles work?
Nano-particles act as a destructive agent on the surface of the filter. The particles are positively or negatively charged and
effectively break down the microbial structure of pathogens coming into contact with the filter.
4. How often do you have to replace the filters?
The active life of the nano-particles is approximately 48 continuous hours. We are recommending replacement at that time.
5. What is the shelf life of the filter?
The shelf life is currently two years. We will continue to adjust shelf life as we are able to test aged inventory for efficacy.
6. Have the filters been tested by a reputable testing facility?
Yes, the filters are tested at Nelson Laboratories in Salt Lake City, UT. Nelson Labs has provided high quality test services to
manufacturers in the medical device, pharmaceutical and nutraceutical industries since 1985. They manage a 62,000 sq. ft. FDA
registered facility in Salt Lake City, UT where they maintain 80 labs along with a custom-built 3,000 sq. ft. cleanroom and employ
over 170 scientists and staff. Among their more than 75 degreed scientists are over 25 registered and specialist
microbiologists (National Registry of Microbiologists). They currently offer more than 400 microbiological and analytical tests and are third-party
certified to ISO 9001 (BSI) and EN 45001/IEC/ISO 17025 standards accredited (AMTAC).
7. Has the NanoMask been approved by NIOSH?
The NanoMask is not yet validated by NIOSH. It was important to validate our nano-particle enhanced filter against bacterial and
viral contaminates and NIOSH was not able to provide this biological validation. They currently test against a challenge of sodium
chloride which is not able to measure the effectiveness of the nano-particle enhancement. We are developing the
nano-particle technology in conjunction with the U.S. Military and sodium chloride testing was not sufficient for our purposes. We are registered
with NIOSH and intend to submit the mask for certification in the near future but found it necessary to validate the bacterial and
viral efficacies of the technology prior to a submission to NIOSH. Please refer to the ‘NIOSH Testing” PDF posted in our web site
for a more detailed explanation.
8. Does the NanoMask fit small children?
The NanoMask is currently available only in an adult size. We are developing a children’s size and hope to have it available by
late November.
9. How do you disinfect the NanoMask?
NIOSH recommends the following for cleaning and
sanitation:
• Remove the filter.
• Wash the frame in warm (43°C/110°F maximum) water with a mild detergent.
• Rinse the mask thoroughly in clean, warm (43°C/110°F maximum), preferably running water.
• If the detergent used does not contain a disinfecting agent immerse the mask for two minutes in a disinfectant water solution such as:
• Quaternary ammonia disinfectant (one packet per 2 gallons or per manufacturer's recommendation).
• Hypochlorite solution (50 ppm of chlorine) made by adding approximately 2 ml of laundry bleach to 1 liter of water at 43°C/110°F.
• Aqueous solution of iodine (50 ppm of iodine) made by adding approximately 0.8 ml of tincture of iodine (approximately 7% ammonium and potassium iodide, 45% alcohol, and 48% water) to 1 liter of water at 43°C/110°F.
• Other commercially available cleansers of equivalent disinfectant quality when used as directed.
• Rinse components thoroughly in clean, warm (43°C/110°F maximum), preferably running water. The importance of thorough
rinsing cannot be overemphasized. Detergents or disinfectants that dry on the frame may result in dermatitis. In addition, some
disinfectants may cause deterioration of rubber if not completely removed.
• Allow the respirator to air dry in a non-contaminated environment.
|
20 Pack of
ADULT SIZE Nano Mask filters ~
Stock up now on Extra Filters
|
ADULT MULTI PACK includes a mask in each color - Blue, Red, Green, Yellow and Magenta.
Comes with two easy-to-insert, replaceable filters. Available in five colors. Protect the whole
business with the Adult Multi-Pack (featuring 5
Adult Masks and 90 filters.) |
|
Click
on the button above
to Buy the 20 Pack of ADULT Filters Now Online... Just
$23.95
|
Click
on the button above
to Buy the ADULT MULTI PACK Now
Online...Just $129.95
|
|
20 Pack of
CHILD SIZE Nano Mask filters ~
Stock up now on Extra Filters
|
FAMILY PACK
Each Mask Comes with two easy-to-insert,
replaceable filters. Available in five colors.
Protect your whole household with the Family Pack (featuring
3 Adult Masks with Filters and 2 Child Masks.) |
|
Click
on the button above
to Buy the 20 Pack of CHILD Filters Now Online... Just
$23.95 |
Click
on the button above
to Buy the FAMILY PACK Now
Online...Just Was $89.95
Now
on Sale for $59.95 |
NEW
100 PACK ASSORTED COLOR ADULT SIZE!
Click on the button above
to Buy 100 Assorted Adult NanoMasks Now
Online...
Was
$19.95
SALE ONLY $7.50 each
|
NEW
100 PACK ASSORTED COLOR CHILD SIZE!
Click on the button above
to Buy 100 Assorted Child NanoMasks Now
Online...
Was
$19.95
SALE ONLY $7.50 each
|
|
|
Home
| Shipping,
Return, Product & Guarantee Policies |
Product
Reviews | Contact
us |
Comments or Questions about this site
Copyright © 2001 - 2006
First-Aid-Product.com, a division of American CPR, all rights reserved
Your source for Airborne Pathogen
Masks, Avian Flu prevention, Protection from SARS Virus, Avian Flu and other air
born pathogens, N95 products and supplies - Masks, Face Shields, and
Filters
- Wholesale to the Public Manufacturer Direct Safety Product Sales since 1993
MORE INFORMATION FROM THE CDC on
Avian Flu Prevention & Protection:
How are avian, pandemic, and seasonal flu
different?
Avian
flu is caused by avian influenza viruses, which occur naturally among birds.
Pandemic flu is flu that causes a
global outbreak, or pandemic, of serious illness that spreads easily from person
to person. Currently there is no pandemic flu.
Seasonal flu is a contagious respiratory
illness caused by influenza viruses.
What You Should Know
Specific Topics
Information for Specific
Groups
Interim
Recommendations for Infection Control in Health-Care Facilities Caring for
Patients with Known or Suspected Avian Influenza
Note: CDC is revising its
interim guidance for infection control precautions for avian influenza. The
revised recommendations will be posted on this website as soon as they are
finalized.
Objective
This document provides interim guidance for
protection of health-care workers involved in the care of patients in the United
States with known or suspected avian influenza. Depending upon where avian
influenza is active in the world, such patients may be recently returning
travelers entering U.S. health-care facilities or individuals who have had close
contact with domestic poultry infected with avian influenza in the United
States. For information regarding the clinical and epidemiologic criteria to be
used in screening patients for possible avian influenza, see the “Update
on Influenza A(H5N1) and SARS: Interim Recommendations for Enhanced U.S.
Surveillance, Testing, and Infection Control” and “Interim
Recommendations for Persons with Possible Exposure to Avian Influenza During
Outbreaks Among Poultry in the United States .”
Background
Influenza viruses that infect primarily birds are
called “avian
influenza viruses.” These type A influenza viruses are genetically
distinguishable from influenza viruses that usually infect people. There are
many subtypes of avian influenza A viruses, including H7 and H5. Avian influenza
viruses can be distinguished as “low pathogenic” and “highly pathogenic”
forms based on genetic features of the virus and the severity of the illness
they cause in poultry.
Avian influenza viruses do not usually infect
humans; however, several instances of human infections and outbreaks of avian
influenza have been reported since 1997 (for more information, see “
Basic Information About Avian Influenza” ). In 2003, influenza A (H7N7)
infections occurred in the Netherlands among persons who handled infected
poultry and among their families during an outbreak of avian flu among poultry.
More than 80 cases of H7N7 illness were confirmed by testing (the symptoms were
mostly confined to eye infections, with some respiratory symptoms), and one
patient died (a veterinarian who had visited an H7N7 influenza-affected farm).
Although there was evidence of limited person-to-person spread of infection,
sustained human-to-human transmission did not occur in this or other outbreaks
of avian influenza. It is believed that most cases of avian influenza infection
in humans have resulted from contact with infected poultry or contaminated
surfaces. However, other means of transmission are also possible, such as the
virus becoming aerosolized and landing on exposed surfaces of the mouth, nose,
or eyes, or being inhaled into the lungs.
Infection and disease in people caused by highly
pathogenic avian influenza H5N1 infection have been identified recently in
Vietnam and Thailand. On February 1, 2004, the World Health Organization (WHO)
reported that laboratory test results had confirmed two fatal cases of human
H5N1 infection in Vietnam in which human-to-human transmission may have
occurred. The cases occurred in two sisters who were part of a cluster of four
cases of severe respiratory illness in a single family. According to WHO,
a detailed investigation of this cluster concluded that limited
human-to-human transmission was one possible explanation, but direct
poultry-to-human transmission could not be ruled out.
The following interim recommendations are based
on what are deemed optimal precautions for protecting individuals involved in
the care of patients with highly pathogenic avian influenza from illness and for
reducing the risk of viral reassortment (i.e., mixing of genes from human and
avian viruses). The ability of low pathogenic avian influenza viruses to cause
infection and serious disease is less well established, but appears to be lower
than that of highly pathogenic viruses based on available information.
Nonetheless, it is considered prudent to take all possible precautions to the
extent feasible when caring for patients with known or possible avian influenza.
Rationale for Enhanced Precautions
Human influenza is thought to transmit primarily
via large respiratory droplets. Standard Precautions plus Droplet Precautions
are recommended for the care of patients infected with human influenza. However,
given the uncertainty about the exact modes by which avian influenza may first
transmit between humans additional precautions for health-care workers involved
in the care of patients with documented or suspected avian influenza may be
prudent. The rationale for the use of additional precautions for avian influenza
as compared with human influenza include the following:
- The risk of serious disease and increased
mortality from highly pathogenic avian influenza may be significantly higher
than from infection by human influenza viruses.
- Each human infection represents an important
opportunity for avian influenza to further adapt to humans and gain the
ability to transmit more easily among people.
- Although rare, human-to-human transmission of
avian influenza may be associated with the possible emergence of a pandemic
strain.
Recommendations for Avian Influenza
All patients who present to a health-care setting
with fever and respiratory symptoms should be managed according to
recommendations for Respiratory
Hygiene and Cough Etiquette and questioned regarding their recent travel
history.
Patients with a history of travel within 10 days
to a country with avian influenza activity and are hospitalized with a severe
febrile respiratory illness, or are otherwise under evaluation for avian
influenza, should be managed using isolation precautions identical to those
recommended for patients with known Severe Acute Respiratory Syndrome (SARS).
These include:
- Standard Precautions
- Pay careful attention to hand hygiene
before and after all patient contact or contact with items potentially
contaminated with respiratory secretions.
- Contact Precautions
- Use gloves and gown for all patient
contact.
- Use dedicated equipment such as
stethoscopes, disposable blood pressure cuffs, disposable thermometers,
etc.
- Eye protection (i.e., goggles
or face shields)
- Wear when within 3 feet of the patient.
- Airborne Precautions
- Place the patient in an airborne isolation
room (AIR). Such rooms should have monitored negative air pressure in
relation to corridor, with 6 to 12 air changes per hour (ACH), and
exhaust air directly outside or have recirculated air filtered by a high
efficiency particulate air (HEPA) filter. If an AIR is unavailable,
contact the health-care facility engineer to assist or use portable HEPA
filters (see Environmental
Infection Control Guidelines) to augment the number of ACH.
- Use a fit-tested respirator, at least as
protective as a National Institute of Occupational Safety and Health
(NIOSH)-approved N-95 filtering facepiece (i.e., disposable) respirator,
when entering the room.

For additional information regarding these and
other health-care isolation precautions, see the Guidelines
for Isolation Precautions in Hospitals. These precautions should be
continued for 14 days after onset of symptoms or until either an alternative
diagnosis is established or diagnostic test results indicate that the patient is
not infected with influenza A virus. Patients managed as outpatients or
hospitalized patients discharged before 14 days with suspected avian influenza
should be isolated in the home setting on the basis of principles outlined for
the home isolation of SARS patients (see http://www.cdc.gov/ncidod/sars/guidance/i/pdf/i.pdf).
Vaccination of Health-Care Workers against Human
Influenza
health-care workers involved in the care of
patients with documented or suspected avian influenza should be vaccinated with
the most recent seasonal human influenza vaccine. In addition to providing
protection against the predominant circulating influenza strain, this measure is
intended to reduce the likelihood of a health-care worker’s being co-infected
with human and avian strains, where genetic rearrangement could take place,
leading to the emergence of potential pandemic strain.
Surveillance and Monitoring of Health-Care
Workers
- Instruct health-care workers to be vigilant
for the development of fever, respiratory symptoms, and/or conjunctivitis
(i.e., eye infections) for 1 week after last exposure to avian
influenza-infected patients.
- Health-care workers who become ill should seek
medical care and, prior to arrival, notify their health-care provider that
they may have been exposed to avian influenza. In addition, employees should
notify occupational health and infection control personnel at their
facility.
- With the exception of visiting a health-care
provider, health-care workers who become ill should be advised to stay home
until 24 hours after resolution of fever, unless an alternative diagnosis is
established or diagnostic tests are negative for influenza A virus.
- While at home, ill persons should practice
good Respiratory
Hygiene and Cough Etiquette to lower the risk of transmission of virus
to others.
This CDC Page last modified May 21, 2004